Medical Business

Business Overview

This business involves the provision of in vitro diagnostic reagents for testing health statuses using, for example, blood and urine. We complete Integrated manufacturing taking in all processes from raw materials to finished products within the Nittobo Group, with the ability to deliver a stable supply of high-quality in vitro diagnostic reagents representing the most distinguishing feature of this business.
These products are renowned for their high quality, and are deployed at healthcare sites throughout the world, and have acquired a large share of the immunoturbidimetry reagents within Japan.
We are striving daily to develop and deliver a stable supply of high-quality in vitro diagnostic reagents to cater to ever-increasing clinical testing needs to the backdrop of an advance in the aging of society and the rise in lifestyle-related diseases.

Products

Refer here for product information and enquiries

Nittobo Medical Co., Ltd.

Nittobo Medical Co., Ltd. offers a large selection of in vitro diagnostic reagents, with a focus on the fields of immunology, biochemistry, and hematology. The Company commenced the manufacture of immunoturbidimetry-related assays in 1988 and has, in particular, earned steadfast trust in this field, with an emphasis on medical institutions, for “Nittobo the immunology specialist.” Nittobo Medical continues today to support healthcare sites both in Japan and throughout the world. In addition to its N-assay series for use with open-system reagents for automated analyzers which are deployed in laboratories of medical institutions and in comprehensive medical exams among other applications, TRACP-5b, which is used in the diagnosis of osteoporosis, and other products, are also highly rated in Japan and overseas.

History of Our Businesses

The medical business made its initial appearance around 1965, at the former Chemical Fiber Laboratory of Nittobo. Around this time, the Chemical Fiber Laboratory shifted its focus from research on synthetic fibers to fine chemicals and, based on the idea that “biochemistry will be the defining chemistry of the next generation,” entered into an entirely new field to its previous business areas.
While this research represents the starting point, we have been developing general chemistry reagents, in response to the expansion of the market for immunoturbidimetric reagents, in 1985, the Company also established partnerships with International Immunology Corporation and Midland BioProducts Corporation (later Nittobo America Inc.), which manufacture antisera for use as the raw materials in immunoturbidimetric reagents. Since then, we have steadily built up our development technologies for in vitro diagnostic reagents as well as our knowhow on antisera production, to create the foundation for our current medical business.

go to top